Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

Shares of Tharimmune Inc. shot up more than 100% in early trading Oct. 30 as the firm disclosed regulatory backing to launch a phase II trial this quarter testing TH-104, a transdermal buccal film ...

In the three aforementioned studies of epidural delivery of naloxone in combination with an opioid (fentanyl or morphine), the frequency of pruritus was decreased, with no reversal of analgesia noted.

Significant progress is being made in the fight against Chronic Kidney Disease-associated Pruritus but sustaining strong ...

Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher Wednesday after the company announced it received overall positive ...

When people think about kidney disease, they often focus on its role in filtering blood, managing fluid levels, and balancing ...

Tharimmune (THAR) received feedback from a Scientific Advice meeting with the European Medicines Agency that included guidance on a planned ...

Charting, Price Performance, News & Related Contracts.

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing ...